Gene DX INC:1108521 [18-030136]
Ended Awarded Last action
- Contract number
- 75N91018F00002
- Awardee
-
Genedx, LLC UEI H3J4SCC8F671 Part of Opko Health, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,500
Award facts
- Contract value 100% obligated
- $10,500.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,313 | |
| Other Administrative Action | $0 | |
| Original award | $11,813 |
About this award
Genedx, LLC was awarded a $10.5K firm fixed-price call under a Blanket Purchase Agreement (BPA) by the National Cancer Institute for germline mutation testing and variant validation in inherited bone marrow failure syndromes. The contract, awarded on July 12, 2018, with an ultimate completion date of May 22, 2023, represents a specialized procurement supporting the NCI's research and clinical objectives. The work was performed at Genedx's laboratory facilities in Potomac, Maryland. This award was not designated as a set-aside contract and reflects Genedx's established capability in genetic testing services within the federal healthcare research marketplace.
Genedx, LLC operates as a wholly owned subsidiary of Opko Health, Inc. and specializes in comprehensive genetic diagnostic services including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial analysis. The company has established itself as a primary provider of genetic testing services to the National Institutes of Health and related federal agencies since its federal registration in May 2008. Beyond this individual BPA call, Genedx holds significant Indefinite Delivery Vehicles with the NIH Clinical Center, including a $1.012M single-award contract for mutation analysis services through June 2024, demonstrating the company's sustained role in supporting federal research and clinical programs requiring advanced genetic diagnostic capabilities.
Quick answers
Who was awarded contract 75N91018F00002?
75N91018F00002 was awarded to Genedx, LLC by National Cancer Institute (National Institutes of Health) on July 12, 2018.
How much is contract 75N91018F00002 worth?
The government has obligated $10,500 on 75N91018F00002.
Is contract 75N91018F00002 an order under another contract?
Yes. 75N91018F00002 is a BPA call under HHSN261201600003B, a blanket purchase agreement.
Was contract 75N91018F00002 competed?
The extent of competition for 75N91018F00002 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award